Compare UNFI & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UNFI | MESO |
|---|---|---|
| Founded | 1976 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 1996 | N/A |
| Metric | UNFI | MESO |
|---|---|---|
| Price | $34.30 | $17.29 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $37.13 | $24.00 |
| AVG Volume (30 Days) | ★ 896.5K | 218.9K |
| Earning Date | 03-10-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $31,753,000,000.00 | $17,198,000.00 |
| Revenue This Year | $2.45 | $576.59 |
| Revenue Next Year | $2.14 | $41.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 1.45 | ★ 191.39 |
| 52 Week Low | $20.78 | $9.61 |
| 52 Week High | $43.29 | $21.50 |
| Indicator | UNFI | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 51.41 | 43.79 |
| Support Level | $32.06 | $16.67 |
| Resistance Level | $35.25 | $18.02 |
| Average True Range (ATR) | 1.20 | 0.68 |
| MACD | 0.21 | -0.30 |
| Stochastic Oscillator | 70.53 | 13.04 |
United Natural Foods Inc is a wholesale distributor of natural, organic and specialty foods and nonfood products across North America. The company's products consist of national, regional and private label brands grouped into grocery and general merchandise, produce, perishables and frozen foods, nutritional supplements and sports nutrition, bulk and foodservice products, and personal care items. United Natural Foods serves various retail formats including conventional supermarket chains, natural product superstores, independent retail operators and foodservice channels such as e-commerce platforms. The company's operations are comprised of principal divisions: the wholesale division; the retail division; and other.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.